Salix Pharmaceuticals, Ltd. Stock

Stocks

15-03-16	Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	RE
15-03-16	Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	RE
15-03-16	Wall St. bounces as dollar drops, Fed worries ease	RE
15-03-16	Endo : withdraws offer for Salix	RE
15-03-11	Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-03-05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-02-24	Shire : buys Meritage Pharma for at least $70 million	RE
15-02-23	Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	RE
15-02-23	Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	RE
15-02-23	BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	RE
15-02-21	Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	RE

15-03-11	Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	BU
15-03-02	Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	BU
15-02-27	Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
15-02-25	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 1.5% Convertible Senior Notes Due 2019	BU
15-02-25	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 2.75% Convertible Senior Notes Due 2015	BU

15-04-01	Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix
15-03-30	Sanofi ne juge pas des acquisitions "indispensables"-Pdt
15-03-16	Le recul du dollar a favorisé le rebond de Wall Street
15-03-16	Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge
15-03-16	BlackBerry : Les valeurs à suivre sur les marchés américains

Manager	Title	Age	Since
Josh Coyle SAM	Sales & Marketing	-	2017-12-31
John Temperato SAM	Sales & Marketing	61	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALIX PHARMACEUTICALS, LTD.	-.--%	+0.16%	-	-	0
ELI LILLY AND COMPANY	+6.63%	+5.13%	+68.86%	+145.20%	1,224B
JOHNSON & JOHNSON	+1.53%	+2.84%	+47.48%	+89.01%	662B
ABBVIE INC.	+1.68%	+1.96%	+29.16%	+109.31%	514B
ROCHE HOLDING AG	+0.73%	+2.45%	+54.26%	+68.96%	388B
MERCK & CO., INC.	+3.83%	-0.62%	+69.01%	+42.32%	361B
NOVARTIS AG	+2.38%	+2.65%	+34.31%	+57.95%	302B
ASTRAZENECA PLC	+2.26%	+0.55%	+3.92%	+28.92%	271B
AMGEN INC.	+1.97%	+3.01%	+57.91%	+76.14%	249B
GILEAD SCIENCES, INC.	+4.03%	+5.36%	+39.76%	+116.14%	205B
Average	+2.11%	+2.59%	+44.96%	+81.55%	464.09B
Weighted average by Cap.	+2.26%	+3.04%	+50.45%	+96.49%

Employees

Sector